EUROFINS GENOMICS FRANCE : revenue, balance sheet and financial ratios
EUROFINS GENOMICS FRANCE is a French company
founded 28 years ago,
specialized in the sector Analyses, essais et inspections techniques.
Based in NANTES (44300),
this company of category GE
shows in 2024 a revenue of 9.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EUROFINS GENOMICS FRANCE (SIREN 418847463)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
9 286 099 €
7 560 379 €
11 053 962 €
11 823 835 €
7 903 635 €
8 026 844 €
7 050 582 €
6 980 533 €
7 070 303 €
Net income
504 258 €
545 394 €
-92 734 €
495 719 €
728 747 €
-1 189 978 €
-83 487 €
194 052 €
461 952 €
EBITDA
-575 413 €
-794 743 €
-1 146 205 €
-240 581 €
-527 036 €
-818 994 €
-422 097 €
-46 641 €
313 824 €
Net margin
5.4%
7.2%
-0.8%
4.2%
9.2%
-14.8%
-1.2%
2.8%
6.5%
Revenue and income statement
Im Jahr 2024 erzielt EUROFINS GENOMICS FRANCE einen Umsatz von 9.3 Mio€. Der Umsatz wächst über 9 Jahre positiv (CAGR: +3.5%). Vs 2023, Wachstum von +23% (7.6 Mio€ -> 9.3 Mio€). Nach Abzug des Verbrauchs (3 k€) beträgt die Bruttomarge 9.3 Mio€, d.h. eine Rate von 100%. Dieses Verhältnis misst die Fähigkeit, aus der Geschäftstätigkeit Wert zu schaffen. EBITDA (= Bruttomarge - Personalkosten - Steuern) erreicht -575 k€, was -6.2% des Umsatzes entspricht. Positiver Schereneffekt: EBITDA-Marge verbessert sich um +4.3 Punkte. Negatives EBITDA bedeutet, dass der Betrieb die laufenden Kosten nicht deckt. Das Nettoergebnis beträgt 504 k€, d.h. 5.4% des Umsatzes.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
9 286 099 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
9 282 867 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
-575 413 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
374 248 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
504 258 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
-6.2%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
Die Verschuldungsquote (= Finanzschulden / Eigenkapital x 100) beträgt 0%. Dieses niedrige Niveau spiegelt eine solide Finanzstruktur wider. Die finanzielle Autonomie (= Eigenkapital / Bilanzsumme x 100) erreicht 6%. Geringe Autonomie: Das Unternehmen ist stark von externer Finanzierung abhängig.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.005%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
5.959%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
-4.671%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
0.0
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution EUROFINS GENOMICS FRANCE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
0.0
0.0
0.0
-0.013
7779.879
0.344
0.0
0.0
0.005
Financial autonomy
13.258
7.538
5.01
-10.479
0.078
6.234
-0.948
6.64
5.959
Repayment capacity
0.0
0.0
0.0
0.0
-0.666
-0.003
0.0
0.0
0.0
Cash flow / Revenue
4.321%
-3.989%
-6.134%
-12.209%
-8.713%
-4.874%
-10.886%
-9.125%
-4.671%
Sector positioning
Verschuldungsgrad
0.012024
2022
2023
2024
Q1: 0.0
Med: 9.99
Q3: 48.5
Ausgezeichnet
Im Jahr 2024 liegt in den unteren 25% der Branche, was positiv ist das verschuldungsgrad von EUROFINS GENOMICS FRANCE (0.01). Dieses Verhältnis misst das Gewicht der Schulden im Verhältnis zum Eigenkapital. Ein niedriges Verhältnis zeigt eine solide Finanzstruktur mit geringer Abhängigkeit von Gläubigern.
Finanzielle Autonomie
5.96%2024
2022
2023
2024
Q1: 11.63%
Med: 34.78%
Q3: 58.76%
Beobachten
Im Jahr 2024 liegt in den unteren 25% der Branche das finanzielle autonomie von EUROFINS GENOMICS FRANCE (6.0%). Dieses Verhältnis stellt den Anteil des Eigenkapitals an der Gesamtfinanzierung dar. Geringe Autonomie kann die Investitionsfähigkeit einschränken und die Verwundbarkeit erhöhen.
Rückzahlungsfähigkeit
0.0 ans2024
2022
2023
2024
Q1: 0.0 ans
Med: 0.0 ans
Q3: 0.87 ans
Ausgezeichnet
Im Jahr 2024 liegt in den unteren 25% der Branche, was positiv ist das rückzahlungsfähigkeit von EUROFINS GENOMICS FRANCE (0.0 an). Dieses Verhältnis gibt die Anzahl der Jahre an, die zur Rückzahlung der Schulden mit dem Cashflow benötigt werden. Eine kurze Kapazität spiegelt kontrollierte Schulden und gute Cashflow-Generierung wider.
Liquidity ratios
Die Liquiditätsquote beträgt 240.59. Das Unternehmen verfügt über 2€ liquide Mittel für jeden 1€ kurzfristiger Schulden.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
240.59
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
-0.997
Liquidity indicators evolution EUROFINS GENOMICS FRANCE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
109.477
100.912
71.368
72.594
230.389
229.975
215.131
252.851
240.59
Interest coverage
3.592
-1.334
-1.78
-3.606
-4.62
-7.449
-0.085
-0.309
-0.997
Sector positioning
Liquiditätsquote
240.592024
2022
2023
2024
Q1: 133.14
Med: 205.95
Q3: 337.03
Gut+7 pts over 3 years
Im Jahr 2024 liegt über dem Median der Branche das liquiditätsquote von EUROFINS GENOMICS FRANCE (240.59). Dieses Verhältnis misst die Fähigkeit, kurzfristige Schulden mit Umlaufvermögen zu decken. Diese komfortable Position bietet eine nennenswerte Sicherheitsmarge.
Zinsdeckung
-1.0x2024
2022
2023
2024
Q1: 0.0x
Med: 0.02x
Q3: 2.48x
Average
Im Jahr 2024 liegt unter dem Median der Branche das zinsdeckung von EUROFINS GENOMICS FRANCE (-1.0x). Dieses Verhältnis gibt an, wie oft das Betriebsergebnis die Zinsaufwendungen deckt. Eine Verbesserung würde die Wettbewerbsposition stärken.
Working capital requirement (WCR) and payment terms
Der Betriebskapitalbedarf (WCR) misst die zeitliche Lücke. Durchschnittliche Kundenzahlungsfrist: 62 Tage. Lieferantenfrist: 59 Tage. Das Unternehmen muss 3 Tage Lücke finanzieren. WCR ist negativ (-32 Tage): Der Betrieb generiert strukturell Liquidität. Bemerkenswerte WCR-Verbesserung über den Zeitraum (-227%), Freisetzung von Liquidität.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
-826 463 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
62 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
59 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
-32 j
WCR and payment terms evolution EUROFINS GENOMICS FRANCE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
650 185 €
692 469 €
-1 431 268 €
-1 914 723 €
-493 898 €
-353 296 €
-1 057 311 €
-1 278 384 €
-826 463 €
Inventory turnover (days)
2
3
0
0
0
0
0
0
0
Customer payment term (days)
62
85
115
126
75
56
73
45
62
Supplier payment term (days)
36
36
66
58
58
46
45
39
59
Positioning of EUROFINS GENOMICS FRANCE in its sector
Comparison with sector Analyses, essais et inspections techniques
Valuation estimate
Indicative estimate only : the number of comparable transactions in this sector is limited (41 transactions).
This range of 637 473€ to 5 243 688€ is provided for information purposes only and requires in-depth analysis to be confirmed.
Estimated enterprise value2024
Indicative
637k€3238k€5243k€
3 238 489 €Range: 637 473€ - 5 243 688€
NAF 5 année 2024
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 41 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Analyses, essais et inspections techniques)
Compare EUROFINS GENOMICS FRANCE with other companies in the same sector:
Frequently asked questions about EUROFINS GENOMICS FRANCE
What is the revenue of EUROFINS GENOMICS FRANCE ?
The revenue of EUROFINS GENOMICS FRANCE in 2024 is 9.3 M€.
Is EUROFINS GENOMICS FRANCE profitable?
Yes, EUROFINS GENOMICS FRANCE generated a net profit of 504 k€ in 2024.
Where is the headquarters of EUROFINS GENOMICS FRANCE ?
The headquarters of EUROFINS GENOMICS FRANCE is located in NANTES (44300), in the department Loire-Atlantique.
Where to find the tax return of EUROFINS GENOMICS FRANCE ?
The tax return of EUROFINS GENOMICS FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EUROFINS GENOMICS FRANCE operate?
EUROFINS GENOMICS FRANCE operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart